X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development

By Gabby Migliara  |    October 18, 2021
A new study from economists at the University of Chicago examined the impact that government price-setting policies for medicines, like those in H.R. 3, could have if implemented. The economists...   Read More

America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach

By Stephen J. Ubl  |    September 15, 2021
Today, PhRMA member companies made public an open letter to Capitol Hill to encourage Congress to abandon old partisan ideas on drug pricing and instead pursue policies that actually address what...   Read More

Recent polling misrepresents public support for Medicare “negotiation”

By Tom Wilbur  |    August 31, 2021
Proponents of government price setting often misrepresent voters’ opinions on support for allowing the federal government to “negotiate” drug prices. This includes recent polling from advocacy...   Read More

What they’re saying: Patient advocates want to protect Medicare from government interference

By Gabby Migliara  |    August 24, 2021
For seniors and people with disabilities, Medicare Parts B and D provide important access to lifesaving medicines. Unfortunately, some in Congress are proposing changes to Medicare under the guise...   Read More

Myth vs. fact: Polling and Medicare “negotiation”

By Tom Wilbur  |    August 12, 2021
As some in Washington consider legislation related to prescription medicines and how to best help Americans manage health care costs, government “negotiation” of prescription medicines within...   Read More

ICYMI: Event spotlights how we can make Medicare work better for patients

By Katie Koziara  |    August 4, 2021
Last month, PhRMA sponsored “Making Medicare Work Better for Patients,” an event hosted by The Hill. During the event, policymakers, patient advocates and biopharmaceutical leaders spoke about how...   Read More

The future of the rebate rule: Will policymakers stand with patients?

By Stephen J. Ubl  |    August 2, 2021
Policymakers will soon decide whether to stand by new Medicare changes that will help lower costs for beneficiaries at the pharmacy counter or abandon these changes to fund government programs...   Read More

Celebrating Medicare’s 56th anniversary

By Gabby Migliara  |    July 30, 2021
For 56 years, Medicare has helped pay for medical care for Americans over the age of 65, as well as younger Americans with certain medical needs. Today marks Medicare’s anniversary and to...   Read More

Government “negotiation” could have devastating consequences for Medicare enrollees

By Gabby Migliara  |    July 23, 2021
Some members of Congress are considering significant changes to Medicare that could have a devastating effect on millions of Americans. Proponents call these changes government “negotiation,” but...   Read More

Protecting Medicare from government interference

By Gabby Migliara  |    July 21, 2021
For more than a decade, Medicare Part D has provided seniors and people with disabilities with affordable and comprehensive prescription medicine coverage. Several surveys show that more than 9 in...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates